Pliant Therapeutics, Inc.(PLRX)

$1.12—

Chart

Pliant Therapeutics, Inc.(PLRX)

NASDAQ

$1.12—

Chart Studio

PLRX(PLRX)

PLRX

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.33

Aug 6, 2026 · Reports before open

Analyst Sentiment

Wall St. Consensus

Hold

15 analysts·Moderate coverage

Score

8 Buy (53%)6 Hold (40%)1 Sell (7%)

Rating Breakdown

Strong Buy

00%

Buy

853%

Hold

640%

Sell

17%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$3.00

+167.9%

Consensus

$3.00

+167.9%

Bull

$3.00

+167.9%

12-Month Target Range15 analysts

$3.00$3.00$3.00

Current $1.12Consensus

Current Price

$1.12

Upside to Consensus

$1.88

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+200.00%

EPS—

FY2028

Rev+100.00%

EPS—

FY2029

Rev+0.00%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$3M	$8M	$15M	$15M	$108M
Low	$3M	$8M	$15M	$15M	$108M
High	$3M	$8M	$15M	$15M	$108M
EBITDA Avg	$-499,999	$-1M	$-3M	$-3M	$-21M
Low	$-499,999	$-1M	$-3M	$-3M	$-21M
High	$-499,999	$-1M	$-3M	$-3M	$-21M
EBIT Avg	$-499,999	$-1M	$-3M	$-3M	$-21M
Low	$-499,999	$-1M	$-3M	$-3M	$-21M
High	$-499,999	$-1M	$-3M	$-3M	$-21M
Net Income Avg	$-86M	$-59M	$-48M	$-65M	$-38M
Low	$-87M	$-65M	$-80M	$-65M	$-38M
High	$-84M	$-53M	$-15M	$-65M	$-38M
EPS Avg	$-1.39	$-0.96	$-0.83	$-1.05	$-0.61
Low	$-1.42	$-1.05	$-1.31	$-1.05	$-0.61
High	$-1.37	$-0.86	$-0.24	$-1.05	$-0.61
Analysts (Rev / EPS)	6 / 3	4 / 3	4 / 4	3 / 2	3 / 2

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	—	$5M	—	—	—	—
Low	—	$5M	—	—	—	—
High	—	$5M	—	—	—	—
EBITDA Avg	—	$-999,999	—	—	—	—
Low	—	$-999,999	—	—	—	—
High	—	$-999,999	—	—	—	—
EBIT Avg	—	$-999,999	—	—	—	—
Low	—	$-999,999	—	—	—	—
High	—	$-999,999	—	—	—	—
Net Income Avg	$-22M	$-23M	$-23M	$-23M	$-25M	$-25M
Low	$-23M	$-23M	$-23M	$-23M	$-25M	$-25M
High	$-22M	$-23M	$-23M	$-23M	$-25M	$-25M
EPS Avg	$-0.36	$-0.37	$-0.38	$-0.38	$-0.40	$-0.40
Low	$-0.37	$-0.37	$-0.38	$-0.38	$-0.40	$-0.40
High	$-0.35	$-0.37	$-0.38	$-0.38	$-0.40	$-0.40
Analysts (Rev / EPS)	— / 3	5 / 1	— / 1	— / 1	— / 1	— / 1

Earnings Surprises

Recent Analyst Actions

Mar 12, 2026Piper Sandler

Pliant Therapeutics (PLRX) PT Lowered to $3 at Piper Sandler

Target:$3.00

+119.8%from $1.36

Mar 3, 2025Stifel Nicolaus

Pliant Therapeutics downgraded to Hold from Buy at Stifel

Target:$3.00

+117.4%from $1.38

Mar 3, 2025Leerink Partners

Pliant Therapeutics downgraded to Market Perform from Outperform at Leerink

Target:$2.00

+44.9%from $1.38

Sep 13, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Pliant Therapeutics (PLRX)

Target:$38.00

+220.9%from $11.84

Sep 9, 2024Leerink Partners

Pliant Therapeutics assumed with an Outperform at Leerink

Target:$33.00

+156.4%from $12.87

May 23, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Pliant Therapeutics (PLRX)

Target:$40.00

+188.8%from $13.85

May 7, 2024Stifel Nicolaus

Pliant Therapeutics (PLRX) PT Lowered to $32 at Stifel

Target:$32.00

+130.1%from $13.91

May 7, 2024Oppenheimer

Pliant Therapeutics (PLRX) PT Raised to $48 at Oppenheimer

Target:$48.00

+248.1%from $13.79

May 7, 2024H.C. Wainwright

Pliant Therapeutics (PLRX) PT Lowered to $36 at H.C. Wainwright

Target:$36.00

+161.1%from $13.79

May 7, 2024RBC Capital

Pliant Therapeutics (PLRX) PT Lowered to $45 at RBC Capital

Target:$45.00

+226.3%from $13.79

Dec 7, 2022J.P. Morgan

JP Morgan Initiates Coverage On Pliant Therapeutics with Overweight Rating, Announces Price Target of $42

Target:$42.00

+144.5%from $17.18

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance